Navigation Links
Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments
Date:11/10/2009

----- ------------ Cash and cash equivalents $4,418,910 $1,102,894 $4,418,910 $1,102,894 Accounts receivable, 278,157 42,279 278,157 42,279 Prepaid expenses and other current assets 80,260 509,168 80,260 509,168 Property and equipment, net 379,646 746,169 379,646 746,169 Other long-term assets 1,704,938 532,438 1,704,938 532,438 Assets of business held for sale - 7,363,973 - 7,363,973 --- --------- --- --------- Total assets $6,861,911 $10,296,921 $6,861,911 $10,296,921 ========== =========== ========== =========== Accounts payable and accrued liabilities $4,300,035 $4,691,600 $4,300,035 $4,691,600 Short-term debt 3,635,661 4,036,776 3,984,467 (3) 6,000,000 Current liabilities of business held for sale - 2,127,986 - (2) 2,127,986 Derivative liabilities 16,343,503 - - (4) - Long-term liabilities 192,672 195,315 192,672 195,315 ------- ------- ------- ------- Total liabilities 24,471,871 11,051,677 8,477,174 13,014,901 ---------- ---------- --------- ---------- Stockholder's deficiency (17,609,960) (754,756) (15,339,085) (2,717,980) ----------- -------- ----------- ---------- Total liabilities and stockholder's deficiency $6,861,911 $10,296,921 $6,861,911 $10,296,921 ====
'/>"/>
SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cardium Announces $5.3 Million Registered Direct Offering
2. Cardium Completes $5.3 Million Registered Direct Offering
3. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
4. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
5. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
6. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
7. Cardium Reports on First Quarter 2008 Highlights and Financial Results
8. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
9. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
10. Cardium Launches New AWARE Clinical Study Website
11. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE MKT: ... of biosimilar therapeutics, today announced that it will be ... Marquis on March 2 nd at 3pm PST. Patrick ... a panel discussing the current state of the biosimilar ... . For more information on CALBIO ...
(Date:2/26/2015)... Feb. 26, 2015 S&P Capital IQ (MHFI) ... Report coverage on MabVax Therapeutics Holdings Inc . ... clinical stage biotechnology company focused on the development of ... in the treatment of cancer. MabVax has discovered a ... protective immune responses generated by patients who have been ...
(Date:2/26/2015)... , Feb. 26, 2015   Regulus Therapeutics ... company leading the discovery and development of innovative medicines ... , Ph.D., President and Chief Executive Officer of Regulus, ... Company 35 th Annual Healthcare Conference on Wednesday, ... is being held at the Boston Marriott Copley Place.  ...
(Date:2/26/2015)... Feb. 26, 2015  NuGene International, Inc. ("NuGene") ... for skin and hair rejuvenation, has announced that ... of record for investor relations and strategic communications. ... distribution, sales and diversification strategies – and we ... prospective shareholders," stated Ali Kharazmi CEO of NuGene ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3
... /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ... company focused on endocrine therapy and oncology, today ... complete the clinical development of the growth hormone ... which could be the first oral diagnostic test ...
... today announced data that showed rapid and sustained improvements ... arthritis (RA) as early as the first week, and ... week 24) following treatment with Cimzia® (certolizumab pegol), together ... Cimzia® is approved for the treatment of adult patients ...
... Forbes Magazine has named Neogen Corporation (Nasdaq: NEOG ) ... America for the eighth time in the last 10 years. , ... Recession: 42% of the companies in the Russell 2000 small-company index ... in the S&P 500," said Forbes, editors in announcing the list. ...
Cached Biology Technology:AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency 2AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency 3UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 2UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 3UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 4UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 5UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 6UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 7UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 8UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 9UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 10UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 11UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 12Neogen Again Named to Forbes' List of Best Small Companies 2
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... including technology and tech stocks, releases video from the CES ... and security consultant Apollo Robbins . Apollo ... the Wocket™ biometric smart wallet, a product of NXT-ID, Inc. ...
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and ... the addition of the "Global Wearable Technologies ... Growth, Share, Overview, Trends and Forecast 2014-2020" ... Wearable Technologies are smart devices that can be ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014  Since its launch in ... of people to eliminate the pain of trying to remember ... their own biometrics fused to their smartphones. To assist people ... Labs , the company that created 1U and focuses on ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3
... Sralini publication, which appeared today in the journal ... Sralini could not be derived from the publication. The ... analysis. VIB points out that Sralini is a ... not one of them has withstood scientific scrutiny. That ...
... the cutting-edge capabilities of the ALMA telescope with newly-developed ... for deciphering the chemistry of the Universe. A research ... of the gas in a star-forming region in the ... telescope and in the laboratory, the scientists were able ...
... in feeding people and restoring their humanity in times of great ... the liberation of Bergen-Belsen at the end of World War Two. ... in the October issue of the Journal of Clinical Nursing ... of the armed forces and medical teams during this distressing time ...
Cached Biology News:Astrochemistry enters a bold new era with ALMA 2Astrochemistry enters a bold new era with ALMA 3Bergen-Belsen lessons underline vital role that nurses can play in patient feeding 2Bergen-Belsen lessons underline vital role that nurses can play in patient feeding 3
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
... Lyophilized solid. Highly active enzyme useful ... of target substrates, and inhibitor screening. Specific ... is defined as the amount of enzyme that will ... hour at 37 C at saturated substrate concentrations. ...
HLA-DRbeta (DA2)...
EML1 (K-16)...
Biology Products: